Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 197-207 , February 2008

Costs of Allogeneic Hematopoietic Cell Transplantation with High-Dose Regimens

  • Akiko M. Saito

      Affiliations

    • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Akiko M. Saito, MD, PhD, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, SM 277, Boston, MA 02115, USA, Phone: 617-632-6637, Fax: 617-632-3161.
    • ,
  • Corey Cutler

      Affiliations

    • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • David Zahrieh

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Robert J. Soiffer

      Affiliations

    • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Vincent T. Ho

      Affiliations

    • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Edwin P. Alyea

      Affiliations

    • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • John Koreth

      Affiliations

    • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Joseph H. Antin

      Affiliations

    • Division of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Stephanie J. Lee

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington

Received 11 September 2007 ,Accepted 25 October 2007.

References 

  1. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491–496
  2. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–762
  3. Sparrelid E, Hagglund H, Remberger M, et al. Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation. Transplant Proc. 1995;27:3530
  4. Hebart H, Loffler J, Meisner C, et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis. 2000;181:1713–1719
  5. Ljungman P, Lore K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1996;17:583–587
  6. Ringden O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. Apmis. 2005;113:813–830
  7. Lee SJ. Outcomes research in hematopoietic cell transplantation. In:  Blume KG,  Forman SJ,  Appelbaum FR editor. Thomas's Hematopoietic Cell Transplantation. 3rd ed.. Malden, Mass:: Blackwell; 2004;p. 434–446
  8. American Cancer Society. Cancer Facts & Figures 2006. Available at http://www.cancer.org/docroot/STT/stt_0.asp Accessed March 21, 2007.
  9. Insurance and Transplant Coverage Information: National Marrow Donor Program. Available at http://www.marrow.org/PATIENT/Plan_for_Tx/Planning_for_Tx_Costs/Insurance_and_Transplant_Cover/index.html. Accessed August 15, 2007.
  10. Kollman C, Weis T, Switzer GE, et al. Non-HLA barriers to unrelated donor stem cell transplantation. Bone Marrow Transplant. 2001;27:581–587
  11. Kline RM, Meiman S, Tarantino MD, et al. A detailed analysis of charges for hematopoietic stem cell transplantation at a children's hospital. Bone Marrow Transplant. 1998;21:195–203
  12. Lee SJ, Klar N, Weeks JC, et al. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64–71
  13. Esperou H, Brunot A, Roudot-Thoraval F, et al. Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study. Transplantation. 2004;77:1854–1858
  14. Griffiths RI, Bass EB, Powe NR, et al. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant. 1993;12:43–48
  15. Matsuo K, Hamajima N, Morishima Y, Harada M. Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2000;26:1061–1067
  16. Freeman M, Vose J, Bennett C, et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant. 1999;24:679–684
  17. Bennett CL, Armitage JL, Armitage GO, et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol. 1995;13:969–973
  18. Masaoka T, Hiraoka A, Okamoto S, et al. Asian Pacific cooperative study of allogeneic bone marrow transplantation. Int J Hematol. 1999;70:190–192
  19. de Lissovoy G, Hurd D, Carter S, et al. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease. Bone Marrow Transplant. 2005;36:539–546
  20. Lee SJ, Zahrieh D, Alyea EP, et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002;100:2697–2702
  21. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867–874
  22. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–1164
  23. Andstrom EE, Ringden O, Remberger M, et al. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycose.s. 1996;39:185–193
  24. Svahn BM, Ringden O, Remberger M. Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades. Transplantation. 2006;81:1600–1603
  25. Saito AM, Zahrieh D, Cutler C, et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007;in press
  26. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplan. 1995;15:825–828
  27. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  28. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–267
  29. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88:3230–3239
  30. Robbins RA, Linder J, Stahl MG, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med. 1989;87:511–518
  31. Chao NJ, Duncan SR, Long GD, et al. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Ann Intern Med. 1991;114:145–146
  32. Mishra V, Vaaler S, Brinch L. A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures. Bone Marrow Transplant. 2001;28:1111–1116
  33. Hsiao WC, Braun P, Yntema D, et al. Estimating physicians' work for a resource-based relative-value scale. N Engl J Med. 1988;319:835–841
  34. Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov. Accessed March 1, 2005.
  35. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. Oxford University Press: New York; 1996;
  36. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  37. Alyea EP, Li S, Kim H, et al. Sirolimus, tacrolimus and reduced-dose methotrexate as graft versus host disease (GVHD) prophylaxis after non-myeloablative stem cell transplantation: low incidence of acute GVHD compared with tacrolimus/methotrexate or cyclosporine/prednisone. Blood. 2004;104:Abstract
  38. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102:1601–1605
  39. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:328–336
  40. van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. 2002;30:243–251
  41. Svahn BM, Alvin O, Ringden O, et al. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82:147–153
  42. Vasiliadis HM, Collet JP, Penrod JR, et al. A cost-effectiveness and cost-utility study of lung transplantation. J Heart Lung Transplant. 2005;24:1275–1283
  43. Ramsey SD, Patrick DL, Albert RK, et al. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest. 1995;108:1594–1601
  44. Anyanwu AC, McGuire A, Rogers CA, et al. An economic evaluation of lung transplantation. J Thorac Cardiovasc Surg. 2002;123:411–418discussion 418-420
  45. Rizzo JD, Vogelsang GB, Krumm S, et al. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting?. J Clin Oncol. 1999;17:2811–2818
  46. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:551–557

PII: S1083-8791(07)00538-1

doi: 10.1016/j.bbmt.2007.10.010

Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 197-207 , February 2008

Article Tools

* Image Usage & Resolution